232 related articles for article (PubMed ID: 30106440)
1. SET7/9 promotes hepatocellular carcinoma progression through regulation of E2F1.
Gu Y; Wang X; Liu H; Li G; Yu W; Ma Q
Oncol Rep; 2018 Oct; 40(4):1863-1874. PubMed ID: 30106440
[TBL] [Abstract][Full Text] [Related]
2. Intestine-specific homeobox (ISX) upregulates E2F1 expression and related oncogenic activities in HCC.
Wang SN; Wang LT; Sun DP; Chai CY; Hsi E; Kuo HT; Yokoyama KK; Hsu SH
Oncotarget; 2016 Jun; 7(24):36924-36939. PubMed ID: 27175585
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of dishevelled 2 is involved in tumor metastasis and is associated with poor prognosis in hepatocellular carcinoma.
Zhang C; Li C; Chen X; Zhou Y; Yin B; Ni R; Zhang Y; Liu J
Clin Transl Oncol; 2017 Dec; 19(12):1507-1517. PubMed ID: 28589433
[TBL] [Abstract][Full Text] [Related]
4. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
[TBL] [Abstract][Full Text] [Related]
6. SIRT5 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting E2F1.
Chang L; Xi L; Liu Y; Liu R; Wu Z; Jian Z
Mol Med Rep; 2018 Jan; 17(1):342-349. PubMed ID: 29115436
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression.
Kang J; Huang X; Dong W; Zhu X; Li M; Cui N
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S257-S268. PubMed ID: 34420405
[TBL] [Abstract][Full Text] [Related]
8. Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins.
Choiniere J; Wu J; Wang L
Mol Pharmacol; 2017 Mar; 91(3):189-196. PubMed ID: 28003426
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms.
Jin Y; Liang ZY; Zhou WX; Zhou L
Hepatol Int; 2019 Mar; 13(2):180-189. PubMed ID: 30600477
[TBL] [Abstract][Full Text] [Related]
10. CAMK2N1 suppresses hepatoma growth through inhibiting E2F1-mediated cell-cycle signaling.
Peng JM; Tseng RH; Shih TC; Hsieh SY
Cancer Lett; 2021 Jan; 497():66-76. PubMed ID: 33068700
[TBL] [Abstract][Full Text] [Related]
11. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
12. Reduced expression of SET7/9, a histone mono-methyltransferase, is associated with gastric cancer progression.
Akiyama Y; Koda Y; Byeon SJ; Shimada S; Nishikawaji T; Sakamoto A; Chen Y; Kojima K; Kawano T; Eishi Y; Deng D; Kim WH; Zhu WG; Yuasa Y; Tanaka S
Oncotarget; 2016 Jan; 7(4):3966-83. PubMed ID: 26701885
[TBL] [Abstract][Full Text] [Related]
13. The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma.
Cui M; Sun J; Hou J; Fang T; Wang X; Ge C; Zhao F; Chen T; Xie H; Cui Y; Yao M; Li J; Li H
Tumour Biol; 2016 Oct; 37(10):13521-13531. PubMed ID: 27465557
[TBL] [Abstract][Full Text] [Related]
14. Hint1 suppresses migration and invasion of hepatocellular carcinoma cells in vitro by modulating girdin activity.
Wu XS; Bao TH; Ke Y; Sun DY; Shi ZT; Tang HR; Wang L
Tumour Biol; 2016 Nov; 37(11):14711-14719. PubMed ID: 27623945
[TBL] [Abstract][Full Text] [Related]
15. Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.
Farra R; Dapas B; Baiz D; Tonon F; Chiaretti S; Del Sal G; Rustighi A; Elvassore N; Pozzato G; Grassi M; Grassi G
Biochimie; 2015 May; 112():85-95. PubMed ID: 25742740
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
Baiz D; Pozzato G; Dapas B; Farra R; Scaggiante B; Grassi M; Uxa L; Giansante C; Zennaro C; Guarnieri G; Grassi G
Biochimie; 2009 Mar; 91(3):373-82. PubMed ID: 19041685
[TBL] [Abstract][Full Text] [Related]
17. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Zhang H; Zheng Z; Zhang R; Yan Y; Peng Y; Ye H; Lin L; Xu J; Li W; Huang P
Cell Death Dis; 2021 Jul; 12(8):731. PubMed ID: 34301921
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of interleukin-32α promotes invasion by modulating VEGF in hepatocellular carcinoma.
Zhao WB; Wang QL; Xu YT; Xu SF; Qiu Y; Zhu F
Oncol Rep; 2018 Mar; 39(3):1155-1162. PubMed ID: 29286122
[TBL] [Abstract][Full Text] [Related]
19. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.
Sueoka S; Kanda M; Sugimoto H; Shimizu D; Nomoto S; Oya H; Takami H; Ezaka K; Hashimoto R; Tanaka Y; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1453-60. PubMed ID: 25805236
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis.
Jin Y; Li Q; Qiu J; Zhao X; Zheng C; Lv S; Bai Y; Shan Y; Ye LC
Tumour Biol; 2016 Oct; 37(10):14193-14203. PubMed ID: 27553024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
